CNTA insider files Form 144 to sell 20,000 shares; recent disposals total 44,000

Rhea-AI Filing Summary

Form 144 filed for Centessa Pharmaceuticals plc (CNTA) shows a proposed sale of 20,000 common shares through UBS Financial Services with an aggregate market value of $440,000.00, listed on Nasdaq. The shares were acquired on 09/10/2025 by exercise of stock options and payment was in cash. The filing notes the issuer has 134,073,436 shares outstanding, and the proposed sale is scheduled for 09/10/2025. The document also discloses sales by the same person totaling 44,000 shares in the past three months for gross proceeds of $761,267.20, with individual sale dates and proceeds listed. The filer affirms no undisclosed material adverse information.

Positive

• Transparent disclosure of broker, acquisition method, dates, and aggregate values in accordance with Rule 144
• Sales documented include exact amounts and gross proceeds, supporting regulatory compliance

Negative

• Insider selling activity of 44,000 shares in the past three months totaling $761,267.20 may concern some investors
• No additional context provided about reasons for sale or any trading plan date under Rule 10b5-1

Insights

Securities Analyst

TL;DR: Insider plans a small sale of exercised options; recent months show multiple disposals totaling 44,000 shares.

The filing documents a routine Form 144 notice for 20,000 shares resulting from a stock option exercise and sale via UBS for an aggregate value of $440,000. Recent disclosed sales by the same person total 44,000 shares for $761,267.20 over four transactions in the prior three months. Relative to the issuer's 134,073,436 shares outstanding, the proposed sale and recent disposals represent an immaterial percentage of the float, suggesting limited immediate dilution or market impact. The filing includes required certifications and no statement of undisclosed material information.

Corporate Governance Expert

TL;DR: Multiple insider sales disclosed; procedural compliance is evident with representation about material information.

The notice shows compliance with Rule 144 disclosure requirements and documents that shares being sold were acquired by option exercise on the same date as the proposed sale. The filer affirms absence of undisclosed material adverse information, and the filing identifies the broker and transaction dates. From a governance perspective, the repeated sales over recent months warrant monitoring but are described transparently in the filing. No governance irregularities or unusual restrictions are stated in the document.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. Eleven Madison Avenue 4th Floor New York NY 10010	20000	440000.00	134073436	09/10/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/10/2025	Exercise of Stock Options	Issuer			20000	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	06/24/2025	12000	168218.40
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	07/15/2025	6000	89566.80
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	08/15/2025	6000	103380.00
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	09/09/2025	20000	400102.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Centessa Pharmaceuticals (CNTA) disclose?

The filing discloses a proposed sale of 20,000 common shares via UBS for $440,000.00, acquired by exercise of stock options on 09/10/2025.

How many shares has the filer sold in the past three months?

The filer sold a total of 44,000 shares in four transactions during the past three months for combined gross proceeds of $761,267.20.

What is Centessa's share count used in the filing?

The filing reports 134,073,436 shares outstanding.

Who is the broker handling the proposed sale?

The broker listed is UBS Financial Services Inc. at Eleven Madison Avenue, New York, NY.

Were the securities acquired as a gift or by purchase?

The securities to be sold were acquired by exercise of stock options and payment was in cash.